Peter C.C. Fong

13.4k total citations · 2 hit papers
102 papers, 5.9k citations indexed

About

Peter C.C. Fong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Peter C.C. Fong has authored 102 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Peter C.C. Fong's work include Prostate Cancer Treatment and Research (47 papers), PARP inhibition in cancer therapy (38 papers) and Cancer Immunotherapy and Biomarkers (24 papers). Peter C.C. Fong is often cited by papers focused on Prostate Cancer Treatment and Research (47 papers), PARP inhibition in cancer therapy (38 papers) and Cancer Immunotherapy and Biomarkers (24 papers). Peter C.C. Fong collaborates with scholars based in United Kingdom, United States and New Zealand. Peter C.C. Fong's co-authors include Johann S. de Bono, David S. Boss, Stan B. Kaye, Timothy A. Yap, Andrew Tutt, Marja Mergui‐Roelvink, Jan H.M. Schellens, James Carmichael, Alan Ashworth and Alan Lau and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Peter C.C. Fong

100 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

2009 2.7k citations Peter C.C. Fong, David S. Boss et al. profile →
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

2010 745 citations Peter C.C. Fong, Timothy A. Yap et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter C.C. Fong United Kingdom	28	3.7k	2.9k	1.4k	1.3k	1.0k	102	5.9k
Rinat Yerushalmi Israel	27	4.4k 1.2×	2.2k 0.8×	1.8k 1.3×	2.3k 1.8×	1.2k 1.1×	119	6.7k
Helen Mackay Canada	41	2.9k 0.8×	2.9k 1.0×	1.2k 0.8×	1.3k 1.0×	644 0.6×	185	7.1k
Alexandra Léary France	38	3.5k 0.9×	2.0k 0.7×	973 0.7×	1.3k 1.0×	680 0.7×	280	7.5k
Helen Swaisland United Kingdom	25	4.8k 1.3×	2.8k 1.0×	2.3k 1.6×	752 0.6×	835 0.8×	50	6.3k
Joaquı́n Mateo United Kingdom	34	3.3k 0.9×	2.1k 0.7×	3.2k 2.2×	1.8k 1.5×	606 0.6×	148	6.1k
David S. Boss Netherlands	14	3.1k 0.8×	2.5k 0.9×	769 0.5×	778 0.6×	939 0.9×	24	4.4k
Kathleen M. Darcy United States	39	1.8k 0.5×	2.1k 0.7×	641 0.4×	961 0.8×	446 0.4×	174	5.1k
Elena López‐Knowles United Kingdom	24	4.3k 1.1×	4.6k 1.6×	1.2k 0.8×	2.1k 1.7×	1.3k 1.3×	46	7.3k
Nilofer S. Azad United States	41	3.8k 1.0×	2.3k 0.8×	1.4k 1.0×	1.3k 1.0×	253 0.2×	205	6.3k
Dongxia Gao Canada	27	2.9k 0.8×	1.5k 0.5×	761 0.5×	2.4k 1.9×	405 0.4×	57	5.1k

Countries citing papers authored by Peter C.C. Fong

Since Specialization

Citations

This map shows the geographic impact of Peter C.C. Fong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter C.C. Fong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter C.C. Fong more than expected).

Fields of papers citing papers by Peter C.C. Fong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter C.C. Fong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter C.C. Fong. The network helps show where Peter C.C. Fong may publish in the future.

Co-authorship network of co-authors of Peter C.C. Fong

This figure shows the co-authorship network connecting the top 25 collaborators of Peter C.C. Fong. A scholar is included among the top collaborators of Peter C.C. Fong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter C.C. Fong. Peter C.C. Fong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fizazi, Karim, Arun Azad, Nobuaki Matsubara, et al.. (2025). Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet. 406(10502). 461–474. 1 indexed citations

Mehra, Niven, Emmanuel S. Antonarakis, Se Hoon Park, et al.. (2025). Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer. European Urology Oncology. 8(4). 1030–1040. 1 indexed citations

Park, S.H., Éric Voog, Wim Demey, et al.. (2024). 1975P Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100. Annals of Oncology. 35. S1144–S1144. 1 indexed citations

Azad, Arun, André P. Fay, Cezary Szczylik, et al.. (2024). 1637P Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study. Annals of Oncology. 35. S987–S988. 1 indexed citations

Matsubara, Nobuaki, Karim Fizazi, Arun Azad, et al.. (2023). 1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status. Annals of Oncology. 34. S977–S978. 3 indexed citations

Desai, Jayesh, Peter C.C. Fong, Víctor Moreno, et al.. (2023). A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. British Journal of Cancer. 128(8). 1418–1428. 10 indexed citations

Fay, André P., Karim Fizazi, Nobuaki Matsubara, et al.. (2023). 1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study. Annals of Oncology. 34. S980–S981. 1 indexed citations

Coleman, Robert L., Amit M. Oza, Domenica Lorusso, et al.. (2022). 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. International Journal of Gynecological Cancer. 32. A226–A226. 16 indexed citations

Dean, Andrew, Amit M. Oza, Domenica Lorusso, et al.. (2020). 821P Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology. 31. S620–S621. 1 indexed citations

10.

Mourey, Loı̈c, Henry Jacob Conter, Neal D. Shore, et al.. (2020). 625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update. Annals of Oncology. 31. S516–S517. 4 indexed citations

11.

Joshua, Anthony M., Howard Gurney, Margitta Retz, et al.. (2020). 217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study. Annals of Oncology. 31. S1325–S1325. 3 indexed citations

12.

Powles, Thomas, Evgeny Kopyltsov, Francis Parnis, et al.. (2020). 745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC). Annals of Oncology. 31. S578–S579. 8 indexed citations

13.

Fong, Peter C.C., Víctor Moreno, Sophia Frentzas, et al.. (2020). 535MO BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma. Annals of Oncology. 31. S468–S469. 1 indexed citations

14.

Fong, Peter C.C., Margitta Retz, Alexandra Drakaki, et al.. (2019). Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). 171–171. 14 indexed citations

15.

Ray‐Coquard, Isabelle, Jubilee Brown, Philipp Harter, et al.. (2014). Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors. International Journal of Gynecological Cancer. 24(9 Suppl 3). S42–S47. 68 indexed citations

16.

Ang, Joo Ern, Charlie Gourley, Hilda A. High, et al.. (2012). Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study.. Journal of Clinical Oncology. 30(15_suppl). 5022–5022. 1 indexed citations

17.

Fong, Peter C.C., Timothy A. Yap, David S. Boss, et al.. (2010). Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. Journal of Clinical Oncology. 28(15). 2512–2519. 745 indexed citations breakdown →

18.

Scott, Edwina N., Anne Thomas, L Rhoda Molife, et al.. (2009). A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 64(2). 425–429. 32 indexed citations

19.

Attard, Gerhardt, Jos Kitzen, Sarah P. Blagden, et al.. (2007). A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. British Journal of Cancer. 97(10). 1338–1343. 52 indexed citations

20.

Fong, Peter C.C., et al.. (1992). Supercritical fluid chromatography and hplc of cyclosporine and fk 506 a new macrolide immunosuppressant. Clinical Chemistry. 38(6). 995–996. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact